Stem Cell Gold Rush
By Jesse Reynolds,
Hartford Courant
| 08. 20. 2006
State Board Rife With Conflicts
Connecticut and a handful of other states are funding human embryonic stem cell research on their own, in reaction to the federal stalemate. Unfortunately, there are signs that Connecticut's $100 million program is rushing forward in a reckless and haphazard way, risking not just millions of taxpayer dollars but the reputation of a line of research that could alleviate suffering.
Although last summer's law creating the program has some admirable points, its key flaw is the composition of the grant-awarding committee. The law's requirements mean that two-thirds of the committee members are involved in stem cell research and likely to be interested in grants themselves.
For example, the board includes Xiangzhong "Jerry" Yang, the state's premier stem cell researcher. Last year, he threatened to move his work to China if the state did not pass the funding bill. Once he was on the committee, he made it clear that he'd be seeking big bucks. He's now applied for $5 million - from his own committee.
Moreover, because Connecticut has only two research universities, conflicts of interest are built in: Committee...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...